Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases

  • Lochmüller, Hanns
  • Badowska, Dorota M.
  • Thompson, Rachel
  • Knoers, Nine V.
  • Aartsma-Rus, Annemieke
  • Gut, Ivo Glynne
  • Wood, Libby
  • Harmuth, Tina
  • Durudas, Andre
  • Graessner, Holm
  • Schaefer, Franz
  • Riess, Olaf
  • RD-Connect consortium
  • NeurOmics consortium
  • EURenOmics consortium
Although individually uncommon, rare diseases (RDs) collectively affect 6-8% of the population. The unmet need of the rare disease community was recognized by the European Commission which in 2012 funded three flagship projects, RD-Connect, NeurOmics, and EURenOmics, to help move the field forward with the ambition of advancing -omics research and data sharing at their core in line with the goals of IRDiRC (International Rare Disease Research Consortium). NeurOmics and EURenOmics generate -omics data and improve diagnosis and therapy in rare renal and neurological diseases, with RD-Connect developing an infrastructure to facilitate the sharing, systematic integration and analysis of these data. Here, we summarize the achievements of these three projects, their impact on the RD community and their vision for the future. We also report from the Joint Outreach Day organized by the three projects on the 3rd of May 2017 in Berlin. The workshop stimulated an open, multi-stakeholder discussion on the challenges of the rare diseases, and highlighted the cross-project cooperation and the common goal: the use of innovative genomic technologies in rare disease research., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, grant agreement n° 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and n° 305608 “EURenOmics”. Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482). We would like to thank Victoria Hedley for her support in dissemination of the RD-Connect project and Ana Töpf for her feedback, which helped to develop the Genome-Phenome Analysis Platform.
Repisalud
Publicación Artículo científico (JournalArticle)

Improving the informed consent process in international collaborative rare disease research: effective consent for effective research

  • Gainotti, Sabina
  • Turner, Cathy
  • Woods, Simon
  • Kole, Anna
  • McCormack, Pauline
  • Lochmüller, Hanns
  • Riess, Olaf
  • Straub, Volker
  • Posada De la Paz, Manuel
  • Taruscio, Domenica
  • Mascalzoni, Deborah
The increased international sharing of data in research consortia and the introduction of new technologies for sequencing challenge the informed consent (IC) process, adding complexities that require coordination between research centres worldwide. Rare disease consortia present special challenges since available data and samples may be very limited. Thus, it is especially relevant to ensure the best use of available resources but at the same time protect patients' right to integrity. To achieve this aim, there is an ethical duty to plan in advance the best possible consent procedure in order to address possible ethical and legal hurdles that could hamper research in the future. Therefore, it is especially important to identify key core elements (CEs) to be addressed in the IC documents for international collaborative research in two different situations: (1) new research collections (biobanks and registries) for which information documents can be created according to current guidelines and (2) established collections obtained without IC or with a previous consent that does not cover all CEs. We propose here a strategy to deal with consent in these situations. The principles have been applied and are in current practice within the RD-Connect consortia - a global research infrastructure funded by the European Commission Seventh Framework program but forward looking in terms of issues addressed. However, the principles established, the lessons learned and the implications for future research are of direct relevance to all internationally collaborative rare-disease projects.
Repisalud
Publicación Artículo de revisión (ReviewArticle)

Current trends in biobanking for rare diseases: a review

  • Graham, Caroline E
  • Molster, Caron
  • Baynam, Gareth
  • Bushby, Kate
  • Hansson, Mats
  • Kole, Anna
  • Mora, Marina
  • Monaco, Lucia
  • Bellgard, Matthew I
  • Carpentieri, David
  • Posada De la Paz, Manuel
  • Riess, Olaf
  • Rubinstein, Yaffa R
  • Schaefer, Franz
  • Taruscio, Domenica
  • Terry, Sharon F
  • Zatloukal, Kurt
  • Knoppers, Bartha
  • Lochmüller, Hanns
  • Dawkins, Hugh
Rare diseases (RD) refer to a collection of approximately 5,000–8,000 individual diseases that have a low prevalence and are often genetic in origin. While RD can manifest throughout life, they frequently affect children and newborns. Common characteristics include being severe, disabling, life-threatening, degenerative and affecting different organ systems. The burden of RD is often exacerbated by a lack of specific treatments. Whilst there is etiological heterogeneity, there is overlap in cellular and molecular pathways. Amongst specialists, there is legitimate hope that based on genetic knowledge and pathway definition, a new medical classification system, currently called “precision medicine”, will be developed, which may change our view on how to apply shared therapeutic targets. Thus, collection of clinical and genetic data and biospecimens (in biobanks) will play an increasing role in diagnoses and development of therapies for RD. Biobanks are maintained collaboratively by researchers or their institutions, and involve a delicate balance between health policy objectives, academic research, public good outcomes, and community trust. Due to the nature of RD, international cooperation is critical for sharing limited numbers of RD samples and achieving a critical mass. Here we review the current and future direction of RD biobanks and discuss research and development stemming from the use of biospecimens to improve management of RD.
Repisalud
Publicación Artículo científico (JournalArticle)

Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications

  • Subías Hidalgo, Marta
  • Yébenes, Hugo
  • Rodríguez-Gallego, César
  • Martín-Ambrosio, Adrián
  • Dominguez-Rodriguez, Mercedes
  • Tortajada, Agustin
  • Rodriguez de Cordoba, Santiago
  • Llorca Blanco, Oscar Antonio
C3 is the central component of the complement system. Upon activation, C3 sequentially generates various proteolytic fragments, C3a, C3b, iC3b, C3dg, each of them exposing novel surfaces, which are sites of interaction with other proteins. C3 and its fragments are therapeutic targets and markers of complement activation. We report the structural and functional characterization of four monoclonal antibodies (mAbs) generated by immunizing C3-deficient mice with a mixture of human C3b, iC3b and C3dg fragments, and discuss their potential applications. This collection includes three mAbs interacting with native C3 and inhibiting AP complement activation; two of them by blocking the cleavage of C3 by the AP C3-converase and one by impeding formation of the AP C3-convertase. The interaction sites of these mAbs in the target molecules were determined by resolving the structures of Fab fragments bound to C3b and/or iC3b using electron microscopy. A fourth mAb specifically recognizes the iC3b, C3dg, and C3d fragments. It binds to an evolutionary-conserved neoepitope generated after C3b cleavage by FI, detecting iC3b/C3dg deposition over opsonized surfaces by flow cytometry and immunohistochemistry in human and other species. Because well-characterized anti-complement mAbs are uncommon, the mAbs reported here may offer interesting therapeutic and diagnostic opportunities.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency

  • Lovric, Svjetlana
  • Goncalves, Sara
  • Gee, Heon Yungy
  • Oskouian, Babak
  • Srinivas, Honnappa
  • Choi, Won-Il
  • Shril, Shirlee
  • Ashraf, Shazia
  • Tan, Weizhen
  • Rao, Jia
  • Airik, Merlin
  • Schapiro, David
  • Braun, Daniela A.
  • Sadowski, Carolin E.
  • Widmeier, Eugen
  • Jobst-Schwan, Tilman
  • Schmidt, Johanna Magdalena
  • Girik, Vladimir
  • Capitani, Guido
  • Suh, Jung H.
  • Lachaussée, Noëlle
  • Arrondel, Christelle
  • Patat, Julie
  • Gribouval, Olivier
  • Furlano, Monica
  • Boyer, Olivia
  • Schmitt, Alain
  • Vuiblet, Vincent
  • Hashmi, Seema
  • Wilcken, Rainer
  • Bernier, Francois P.
  • Innes, A. Micheil
  • Parboosingh, Jillian S.
  • Lamont, Ryan E.
  • Midgley, Julian P.
  • Wright, Nicola
  • Majewski, Jacek
  • Zenker, Martin
  • Schaefer, Franz
  • Kuss, Navina
  • Greil, Johann
  • Giese, Thomas
  • Schwarz, Klaus
  • Catheline, Vilain
  • Schanze, Denny
  • Franke, Ingolf
  • Sznajer, Yves
  • Truant, Anne S.
  • Adams, Brigitte
  • Desir, Julie
  • Biemann, Ronald
  • Pei, York
  • Ars, Elisabet
  • Lloberas Blanch, Núria
  • Madrid, Alvaro
  • Dharnidharka, Vikas R.
  • Connolly, Anne M.
  • Willing, Marcia C.
  • Cooper, Megan A.
  • Lifton, Richard P
  • Simons, Matias
  • Riezman, Howard
  • Antignac, Corinne
  • Saba, Julie D.
  • Hildebrandt, Friedhelm
Steroid-resistant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease cases. A mutation in 1 of over 40 monogenic genes can be detected in approximately 30% of individuals with SRNS whose symptoms manifest before 25 years of age. However, in many patients, the genetic etiology remains unknown. Here, we have performed whole exome sequencing to identify recessive causes of SRNS. In 7 families with SRNS and facultative ichthyosis, adrenal insufficiency, immunodeficiency, and neurological defects, we identified 9 different recessive mutations in SGPL1, which encodes sphingosine-1-phosphate (S1P) lyase. All mutations resulted in reduced or absent SGPL1 protein and/or enzyme activity. Overexpression of cDNA representing SGPL1 mutations resulted in subcellular mislocalization of SGPL1. Furthermore, expression of WT human SGPL1 rescued growth of SGPL1-deficient dpl1. yeast strains, whereas expression of disease-associated variants did not. Immunofluorescence revealed SGPL1 expression in mouse podocytes and mesangial cells. Knockdown of Sgpl1 in rat mesangial cells inhibited cell migration, which was partially rescued by VPC23109, an S1P receptor antagonist. In Drosophila, Sply mutants, which lack SGPL1, displayed a phenotype reminiscent of nephrotic syndrome in nephrocytes. WT Sply, but not the disease-associated variants, rescued this phenotype. Together, these results indicate that SGPL1 mutations cause a syndromic form of SRNS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin

  • Alcorlo, Martín
  • Tortajada, Agustín
  • Rodríguez de Córdoba, Santiago
  • Llorca, Óscar
33 p.-4 fig.-2 fig. supl., Complement is an essential component of innate immunity. Its activation results in the assembly of unstable protease complexes, denominated C3/C5 convertases, leading to inflammation and lysis. Regulatory proteins inactivate C3/C5 convertases on host surfaces to avoid collateral tissue damage. On pathogen surfaces, properdin stabilizes C3/C5 convertases to efficiently fight infection. How properdin performs this function is, however, unclear. Using electron microscopy we show that the N-and C-terminal ends of adjacent monomers in properdin oligomers conform a curly vertex that holds together the AP convertase, interacting with both the C345C and vWA domains of C3b and Bb, respectively. Properdin also promotes a large displacement of the TED (thioestercontaining domain) and CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) domains of C3b, which likely impairs C3-convertase inactivation by regulatory proteins. The combined effect of molecular cross-linking and structural reorganization increases stability of the C3 convertase and facilitates recruitment of fluid-phase C3 convertase to the cell surfaces. Our model explains how properdin mediates the assembly of stabilized C3/C5-convertase clusters, which helps to localize complement amplification to pathogen surfaces., This work was funded by the Autonomous Region of Madrid (S2010/BMD-2316 to S.R.d.C. and O.L.), the Ramón Areces Foundation (O.L.), and the Spanish government (SAF2011-22988 to O.L. and SAF2011-26583 to S.R.d.C.). O.L. is additionally supported by Red Temática de Investigación Cooperativa en Cáncer (RD06/0020/1001), and S.R.d.C. is also supported by the Fundación Renal Iñigo Alvarez de Toledo and the Seventh Framework Programme European Union Project EURenOmics (European Consortium for High-Throughput Research in Rare Kidney Diseases-305608)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene

  • Román-Ortiz, E.
  • Mendizabal Oteiza, S.
  • Pinto, Sheila
  • López-Trascasa, Margarita
  • Sánchez-Corral, Pilar
  • Rodríguez de Córdoba, Santiago
16 p.-1 tab.-1 fig., Background: Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes present a very high risk of recurrence despite preventive plasmapheresis. Evaluation of recent data suggests that prophylactic eculizumab pretransplant might be the preferred therapy if available. Case-diagnosis/treatment: We report 3-year follow-up data in a 9-year-old boy with aHUS and successful renal transplant treated with prophylactic eculizumab without recurrence. He presented with aHUS at age 3, irreversible renal failure and uncontrolled severe hypertension with concentric left ventricular hypertrophy, recurrent acute pulmonary edema, and congestive heart failure despite five hypotensive agents and bilateral nephrectomy. Complement analysis demonstrated the presence of a CFH/CFHR1 hybrid gene inherited from his mother and a SNP risk CFH haplotype inherited from his father. Kidney transplant was performed with prophylactic eculizumab and subsequent fortnightly administration. Three years post-transplant, graft function remains stable (serum creatinine 0.9 mg/dl), hypertension is controlled, no left ventricular hypertrophy, no opportunistic infections, and negative clinical chemistry parameters for hemolysis. Conclusion: Eculizumab is a safe and effective therapy for preventing TMA recurrence and provides long-term graft function in aHUS with the CFH/CFHR1 hybrid gene. © 2013 IPNA., SRdeC is supported by the Spanish Ministerio de Economía y Competitividad [Ministry of Finance and Competition] (SAF2011-26583), the Comunidad de Madrid [Autonomous Region of Madrid] (S2010/BMD-2316), the European Union FP7 (EURENOMICS) and the Fundación Renal Iñigo Alvarez de Toledo. PSC is supported by the Spanish Ministerio de Economía y Competitividad (PS09-00268), and the Comunidad de Madrid (S2010/BMD-2316).MLT is supported by the Spanish Ministerio de Economía y Competitividad (PS09- 00122), and the Comunidad de Madrid (S2010/BMD-2316)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ionic tethering contributes to the conformational stability and function of complement C3b, Ionic tethering and conformational stability of C3b

  • López-Perrote, Andrés
  • Harrison, Reed E. S.
  • Subías, Marta
  • Alcorlo, Martín
  • Rodríguez de Córdoba, Santiago
  • Morikis, Dimitrios
  • Llorca, Óscar
C3b, the central component of the alternative pathway (AP) of the complement system, coexists as a mixture of conformations in solution. These conformational changes can affect interactions with other proteins and complement regulators. Here we combine a computational model for electrostatic interactions within C3b with molecular imaging to study the conformation of C3b. The computational analysis shows that the TED domain in C3b is tethered ionically to the macroglobulin (MG) ring. Monovalent counterion concentration affects the magnitude of electrostatic forces anchoring the TED domain to the rest of the C3b molecule in a thermodynamic model. This is confirmed by observing NaCl concentration dependent conformational changes using single molecule electron microscopy (EM). We show that the displacement of the TED domain is compatible with C3b binding to Factor B (FB), suggesting that the regulation of the C3bBb convertase could be affected by conditions that promote movement in the TED domain. Our molecular model also predicts mutations that could alter the positioning of the TED domain, including the common R102G polymorphism, a risk variant for developing age-related macular degeneration. The common C3b isoform, C3bS, and the risk isoform, C3bF, show distinct energetic barriers to displacement in the TED that are related to a network of electrostatic interactions at the interface of the TED and MG-ring domains of C3b. These computational predictions agree with experimental evidence that shows differences in conformation observed in C3b isoforms purified from homozygous donors. Altogether, we reveal an ionic, reversible attachment of the TED domain to the MG ring that may influence complement regulation in some mutations and polymorphisms of C3b., Work in this report has been funded by the Spanish Ministry of Economy and Competitiveness (SAF2011-26583 to SRC and SAF2014-52301-R to OL), the Fundación Renal Iñigo Alvarez de Toledo and the Seventh Framework Programme European Union Project EURenOmics (305608) to SRC. In addition, this work has been supported by a grant from the Autonomous Region of Madrid (S2010/BMD-2316) to SRC and OL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Eculizumab in secondary atypical haemolytic uraemic syndrome

  • Cavero, Teresa
  • Arjona, Emilia
  • Rodríguez de Córdoba, Santiago
  • Praga, Manuel
9 p.-1 fig.-7 tab. Cavero, Teresa et al., Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab., Methods. We identified 29 patients with so-called secondary aHUS who had received eculizumab at 11 Spanish nephrology centres. Primary outcome was TMA resolution, defined by a normalization of platelet count (>150 109/L) and haemoglobin, disappearance of all the markers of microangiopathichaemolytic anaemia (MAHA), and improvement of renal function,with a 25% reduction of serum creatinine from the onset of eculizumab administration., Results. Twenty-nine patients with secondary aHUS (15 druginduced,8 associated with systemic diseases, 2 with postpartum,2 with cancer-related, 1 associated with acute humoral rejectionand 1 with intestinal lymphangiectasia) were included in this study. The reason to initiate eculizumab treatment was worsening of renal function and persistence of TMA despite treatment of the TMA cause and plasmapheresis. All patients showed severe MAHA and renal function impairment (14 requiring dialysis) prior to eculizumab treatment and 11 presented severe extrarenal manifestations. A rapid resolution of the TMA was observed in 20 patients (68%), 15 of them showing a _>50% serum creatinine reduction at the last follow-up. Comprehensive genetic and molecular studies in 22 patients identified complement pathogenic variants in only 2 patients. With these two exceptions, eculizumab was discontinued, after a median of 8 weeks of treatment, without the occurrence of aHUS relapses., Conclusion. Short treatment with eculizumab can result in a rapid improvement of patients with secondary aHUS in whom TMA has persisted and renal function worsened despite treatment of the TMA-inducing condition., Work in this report was funded by the Instituto de Salud Carlos III: REDinREN (RD 016/009 Feder Funds), the Fondo de Investigaciones Sanitarias (13/02502 and ICI14/00350), the Ministerio de Economia y Competitividad (SAF2015-66287R) and the Autonomous Region of Madrid (S2010/BMD-2316;Grupo de Investigación Complemento-CM). SRdeC is funded by the Seventh Framework Programme European UnionProject EURenOmics (305608)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications

  • Subías, Marta
  • Yébenes, Hugo
  • Rodríguez-Gallego, César
  • Martín-Ambrosio, Adrián
  • Domínguez, Mercedes
  • Tortajada, Agustín
  • Rodríguez de Córdoba, Santiago
  • Llorca, Óscar
41 p.-11 fig., C3 is the central component of the complement system. Upon activation, C3 sequentially generates various proteolytic fragments, C3a, C3b, iC3b, C3dg, each of them exposing novel surfaces, which are sites of interaction with other proteins. C3 and its fragments are therapeutic targets and markers of complement activation. We report the structural and functional characterization of four monoclonal antibodies (mAbs) generated by immunizing C3-deficient mice with a mixture of human C3b, iC3b and C3dg fragments, and discuss their potential applications. This collection includes three mAbs interacting with native C3 and inhibiting AP complement activation; two of them by blocking the cleavage of C3 by the AP C3-converase and one by impeding formation of the AP C3-convertase. The interaction sites of these mAbs in the target molecules were determined by resolving the structures of Fab fragments bound to C3b and/or iC3b using electron microscopy. A fourth mAb specifically recognizes the iC3b, C3dg, and C3d fragments. It binds to an evolutionary-conserved neoepitope generated after C3b cleavage by FI, detecting iC3b/C3dg deposition over opsonized surfaces by flow cytometry and immunohistochemistry in human and other species. Because well-characterized anti-complement mAbs are uncommon, the mAbs reported here may offer interesting therapeutic and diagnostic opportunities., Work in this report has been funded by the Spanish “Ministerio de Economía y Competitividad” (SAF2011-26583 and SAF2015-66287-R to SRdC and SAF2014- 52301-R to OL) and the Seventh Framework Programme European Union Project EURenOmics (305608) to SRdC. In addition, this work has been supported by a grant from the Autonomous Region of Madrid (S2010/BMD-2316) to SRdeC and OL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

How novel structures inform understanding of complement function

  • Goicoechea de Jorge, Elena
  • Yébenes, Hugo
  • Serna, Marina
  • Tortajada, Agustín
  • Llorca, Óscar
  • Rodríguez de Córdoba, Santiago
33 p.-3 fig., During the last decade, the complement field has experienced outstanding advancements in the mechanistic understanding of how complement activators are recognized, what C3 activation means, how protein complexes like the C3 convertases and the membrane attack complex are assembled, and how positive and negative complement regulators perform their function. All of this has been made possible mostly because of the contributions of structural biology to the study of the complement components. The wealth of novel structural data has frequently provided support to previously held knowledge, but often has added alternative and unexpected insights into complement function. Here we will review some of these findings focusing in the alternative and terminal complement pathways., SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608) and the Autonomous Region of Madrid (S2010/BMD- 2316). SRdeC is member of the “CIB intramural Program “Molecular Machines for Better Life (MACBET)”. EGdeJ is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (RYC-2013-13395 and SAF2014-52339P). OL is supported by the Spanish Ministry of Economy, Industry and Competitiveness (SAF2014-52301-R).AT and MS are supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (IJCI-2015-25222 and IJCI-2015-24388, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome

  • Goicoechea de Jorge, Elena
  • Tortajada, Agustín
  • Pinto, Sheila
  • Gastoldi, Sara
  • Martín Merinero, Héctor
  • García-Fernández, Jesús
  • Arjona, Emilia
  • Cao, Mercedes
  • Remuzzi, Giuseppe
  • Noris, Marina
  • Rodríguez de Córdoba, Santiago
10 p.-6 fig.-1 tab., Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants, mainly affects the kidney microvasculature. A retrospective genetic analysis in our aHUS cohort (n=513) using multiple ligation probe amplification uncovered nine unrelated patients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originates by recurrent gene conversion events between the CFH and CFHR1 genes. The novel CFHR1 mutants encode an FHR-1 protein with two amino acid substitutions, L290S and A296V, converting the FHR-1 C terminus into that of factor H (FH). Next-generation massive-parallel DNA sequencing (NGS) analysis did not detect these genetic abnormalities. In addition to the CFHR1 mutant, six patients carried the previously uncharacterized CFH-411T variant. In functional analyses, the mutant FHR-1 protein strongly competed the binding of FH to cell surfaces, impairing complement regulation, whereas the CFH-411T polymorphism lacked functional consequences. Carriers of the CFHR1 mutation presented with severe aHUS during adulthood; 57% of affected women in this cohort presented during the postpartum period. Analyses in patients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome modulate disease penetrance. Crucially, in the activated endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome correlated inversely with impairment of complement regulation, measured as C5b-9 deposition. Our data advance understanding of the genetic complexities underlying aHUS, illustrate the importance of performing functional analysis, and support the use of complementary assays to disclose genetic abnormalities not revealed by current NGS analysis., S.R.d.C. is supported by the Spanish “Ministerio de Economía y Competitividad-Federación Española de Enfermedades Raras (FEDER)” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608), and the Autonomous Region of Madrid (S2010/BMD-2316). S.R.d.C. is member of the “Centro de Investigaciones Biológicas Intramural Program “Molecular Machines for Better Life” (MACBET).” E.G.d.J. is supported by the Spanish “Ministerio de Economía y Competitividad” (RYC-2013-13395 and SAF2014-52339P). M.N. is supported by the Seventh Framework Programme European Union Project EURenOmics (305608). This study was also partially supported by Redes Tematicas De Investigacion Cooperativa En Salud, Red de Investigación Renal (RD06/0016/1002 and RD12/0028), the Instituto de Salud Carlos III, and the Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome, Pregnancy-associated atypical hemolytic uremic syndrome; a retrospective study from the Spanish Registry.

  • Huerta, Ana
  • Arjona, Emilia
  • Portoles, Jose
  • Lopez-Sanchez, Paula
  • Rabasco, Cristina
  • Espinosa, Mario
  • Cavero, Teresa
  • Blasco, Miquel
  • Cao, Mercedes
  • Manrique, Joaquin
  • Cabello-Chaves, Virginia
  • Suñer, Marta
  • Heras, Manuel
  • Fulladosa, Xavier
  • Belmar-Vega, Lara
  • Sempere, Amparo
  • Peralta, Carmen
  • Castillo, Lorena
  • Arnau, Alvaro
  • Praga, Manuel
  • Rodríguez de Córdoba, Santiago
34 p.-2 fig.-3 tab., Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) refers to the thrombotic microangiopathy resulting from uncontrolled complement activation during pregnancy or the postpartum period. Pregnancy-associated aHUS is a devastating disease for which there is a limited clinical understanding and treatment experience. Here we report a retrospective study to analyze the clinical and prognostic data of 22 cases of pregnancy-associated aHUS from the Spanish aHUS Registry under different treatments. Sixteen patients presented during the first pregnancy and as many as nine patients required hemodialysis at diagnosis. Identification of inherited complement abnormalities explained nine of the 22 cases, with CFH mutations and CFH to CFHR1 gene conversion events being the most prevalent genetic alterations associated with this disorder (66%). In thirteen of the cases, pregnancy complications were sufficient to trigger a thrombotic microangiopathy in the absence of genetic or acquired complement alterations. The postpartum period was the time with highest risk to develop the disease and the group shows an association of cesarean section with pregnancy-associated aHUS. Seventeen patients underwent plasma treatments with a positive renal response in only three cases. In contrast, ten patients received eculizumab with an excellent renal response in all, independent of carrying or not inherited complement abnormalities. Although the cohort is relatively small, the data suggest that pregnancy-associated aHUS is not different from other types of aHUS and suggest the efficacy of eculizumab treatment over plasma therapies. This study may be useful to improve prognosis in this group of aHUS patients., Work in this report was funded by the Instituto de Salud Carlos III: REDinREN (RD016/009 and RD012/0021) and Fondo de Investigaciones Sanitarias (ISCIII/FEDER) ref 13/02502 and ref 16/01685. SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608) and the Autonomous Region of Madrid (S2010/BMD-2316)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Complete functional characterization of disease-associated genetic variants in the complement factor H gene

  • Martín Merinero, Héctor
  • Pinto, Sheila
  • García-Fernández, Jesús
  • Arjona, Emilia
  • Tortajada, Agustín
  • Rodríguez de Córdoba, Santiago
30 p.-7 fig., Genetic analyses in atypical hemolytic uremic syndrome (aHUS) and C3-glomerulopathy (C3G) patients have provided an excellent understanding of the genetic component of the disease and informed genotype-phenotype correlations supporting an individualized approach to patient management and treatment. In this context, a correct categorization of the disease-associated gene variants is critical to avoid detrimental consequences for patients and their relatives. Here we describe a comprehensive procedure to measure levels and functional activity of complement regulator factor H (FH) encoded by CFH, the commonest genetic factor associated with aHUS and C3G, and present the results of the analysis of 28 uncharacterized, disease-associated, FH variants. Sixteen variants were not expressed in plasma and eight had significantly reduced functional activities that impact on complement regulation. In total, 24 of 28 CFH variants were unambiguously categorized as pathogenic and the nature of the pathogenicity fully documented for each. The data also reinforce the genotype-phenotype correlations that associate specific FH functional alterations with either aHUS or C3G and illustrate important drawbacks of the prediction algorithms dealing with variants located in FH functional regions. We also report that the novel aHUS-associated M823T variant is functionally impaired. This was unexpected and uncovered the important contribution of regions outside the N-terminal and C-terminal functional domains to FH regulatory activities on surfaces. Thus, our work significantly advances knowledge towards a complete functional understanding of the CFH genetic variability and highlights the importance of functional analysis of the disease-associated CFH variants., SRdeC is supported by the Spanish Ministerio de Economía y Competitividad/FEDER (grant number SAF2015-66287-R), the Seventh Framework Programme European Union Project EURenOmics (grantnumber 305608), and the Autonomous Region of Madrid (grantnumber S2010/BMD-2316)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases

  • Lochmüller, Hanns
  • Badowska, Dorota M.
  • Thompson, Rachel
  • Knoers, Nine V.
  • Aartsma-Rus, Annemieke
  • Gut, Ivo Glynne
  • Wood, Libby
  • Harmuth, Tina
  • Durudas, Andre
  • Graessner, Holm
  • Schaefer, Franz
  • Riess, Olaf
  • RD-Connect consortium
  • NeurOmics consortium
  • EURenOmics consortium
Although individually uncommon, rare diseases (RDs) collectively affect 6-8% of the population. The unmet need of the rare disease community was recognized by the European Commission which in 2012 funded three flagship projects, RD-Connect, NeurOmics, and EURenOmics, to help move the field forward with the ambition of advancing -omics research and data sharing at their core in line with the goals of IRDiRC (International Rare Disease Research Consortium). NeurOmics and EURenOmics generate -omics data and improve diagnosis and therapy in rare renal and neurological diseases, with RD-Connect developing an infrastructure to facilitate the sharing, systematic integration and analysis of these data. Here, we summarize the achievements of these three projects, their impact on the RD community and their vision for the future. We also report from the Joint Outreach Day organized by the three projects on the 3rd of May 2017 in Berlin. The workshop stimulated an open, multi-stakeholder discussion on the challenges of the rare diseases, and highlighted the cross-project cooperation and the common goal: the use of innovative genomic technologies in rare disease research., This work has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant agreement n° 305444 “RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research”, grant agreement n° 2012-305121 “Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases (NEUROMICS)” and n° 305608 “EURenOmics”. Hanns Lochmüller has received funding from the Medical Research Council UK (grant reference G1002274, grant ID 98482). We would like to thank Victoria Hedley for her support in dissemination of the RD-Connect project and Ana Töpf for her feedback, which helped to develop the Genome-Phenome Analysis Platform.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency

  • Lovric, Svjetlana
  • Goncalves, Sara
  • Gee, Heon Yungy
  • Oskouian, Babak
  • Srinivas, Honnappa
  • Choi, Won-Il
  • Shril, Shirlee
  • Ashraf, Shazia
  • Tan, Weizhen
  • Rao, Jia
  • Airik, Merlin
  • Schapiro, David
  • Braun, Daniela A.
  • Sadowski, Carolin E.
  • Widmeier, Eugen
  • Jobst-Schwan, Tilman
  • Schmidt, Johanna Magdalena
  • Girik, Vladimir
  • Capitani, Guido
  • Suh, Jung H.
  • Lachaussée, Noëlle
  • Arrondel, Christelle
  • Patat, Julie
  • Gribouval, Olivier
  • Furlano, Monica
  • Boyer, Olivia
  • Schmitt, Alain
  • Vuiblet, Vincent
  • Hashmi, Seema
  • Wilcken, Rainer
  • Bernier, Francois P.
  • Innes, A. Micheil
  • Parboosingh, Jillian S.
  • Lamont, Ryan E.
  • Midgley, Julian P.
  • Wright, Nicola
  • Majewski, Jacek
  • Zenker, Martin
  • Schaefer, Franz
  • Kuss, Navina
  • Greil, Johann
  • Giese, Thomas
  • Schwarz, Klaus
  • Catheline, Vilain
  • Schanze, Denny
  • Franke, Ingolf
  • Sznajer, Yves
  • Truant, Anne S.
  • Adams, Brigitte
  • Desir, Julie
  • Biemann, Ronald
  • Pei, York
  • Ars, Elisabet
  • Lloberas Blanch, Núria
  • Madrid, Alvaro
  • Dharnidharka, Vikas R.
  • Connolly, Anne M.
  • Willing, Marcia C.
  • Cooper, Megan A.
  • Lifton, Richard P
  • Simons, Matias
  • Riezman, Howard
  • Antignac, Corinne
  • Saba, Julie D.
  • Hildebrandt, Friedhelm
Steroid-resistant nephrotic syndrome (SRNS) causes 15% of chronic kidney disease cases. A mutation in 1 of over 40 monogenic genes can be detected in approximately 30% of individuals with SRNS whose symptoms manifest before 25 years of age. However, in many patients, the genetic etiology remains unknown. Here, we have performed whole exome sequencing to identify recessive causes of SRNS. In 7 families with SRNS and facultative ichthyosis, adrenal insufficiency, immunodeficiency, and neurological defects, we identified 9 different recessive mutations in SGPL1, which encodes sphingosine-1-phosphate (S1P) lyase. All mutations resulted in reduced or absent SGPL1 protein and/or enzyme activity. Overexpression of cDNA representing SGPL1 mutations resulted in subcellular mislocalization of SGPL1. Furthermore, expression of WT human SGPL1 rescued growth of SGPL1-deficient dpl1. yeast strains, whereas expression of disease-associated variants did not. Immunofluorescence revealed SGPL1 expression in mouse podocytes and mesangial cells. Knockdown of Sgpl1 in rat mesangial cells inhibited cell migration, which was partially rescued by VPC23109, an S1P receptor antagonist. In Drosophila, Sply mutants, which lack SGPL1, displayed a phenotype reminiscent of nephrotic syndrome in nephrocytes. WT Sply, but not the disease-associated variants, rescued this phenotype. Together, these results indicate that SGPL1 mutations cause a syndromic form of SRNS.